PriceTargets.com logo

SCYNEXIS - SCYX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.67
  • Forecasted Upside: 338.10%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.75 As of 01/26/2023 01:00 AM ET
▲ +0.03 (1.74%)

This chart shows the closing price for SCYX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SCYNEXIS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCYX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCYX

Analyst Price Target is $7.67
▲ +338.10% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for SCYNEXIS in the last 3 months. The average price target is $7.67, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 338.10% upside from the last price of $1.75.

This chart shows the closing price for SCYX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in SCYNEXIS. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/4/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/25/2022Maxim GroupLower Target$11.00 ➝ $7.00Low
10/21/2022Brookline Capital AcquisitionReiterated RatingBuy$8.00Low
5/13/2022HC WainwrightLower Target$14.00 ➝ $8.00High
3/31/2022HC WainwrightLower TargetBuy$20.00 ➝ $14.00Medium
8/24/2021Brookline Capital ManagementReiterated RatingBuyLow
6/30/2021HC WainwrightReiterated RatingBuy$20.00Medium
6/7/2021AegisLower TargetBuy$40.00 ➝ $35.00Low
6/3/2021HC WainwrightReiterated RatingBuyMedium
5/18/2021HC WainwrightReiterated RatingBuyHigh
4/12/2021AegisLower TargetBuy$45.00 ➝ $40.00High
2/17/2021Maxim GroupBoost TargetBuy$17.00 ➝ $22.00Low
2/15/2021AegisReiterated RatingBuyHigh
1/22/2021GuggenheimInitiated CoverageBuy$25.00High
1/5/2021Cantor FitzgeraldInitiated CoverageOverweight$30.00N/A
12/28/2020HC WainwrightLower TargetBuy$35.00 ➝ $20.00N/A
12/23/2020Maxim GroupReiterated RatingBuy$17.00N/A
11/6/2020Maxim GroupReiterated RatingBuy$15.00High
8/11/2020LADENBURG THALM/SH SHReiterated RatingBuy$25.00High
8/10/2020Needham & Company LLCInitiated CoverageBuy$50.00High
7/15/2020Needham & Company LLCReiterated RatingBuy$50.00High
5/31/2020AegisReiterated RatingBuy$45.00High
5/19/2020HC WainwrightReiterated RatingBuy$35.00Medium
5/11/2020Needham & Company LLCReiterated RatingBuy$50.00Low
4/23/2020AegisBoost TargetBuy$40.00 ➝ $45.00High
4/22/2020Maxim GroupReiterated RatingBuy$40.00Medium
4/22/2020HC WainwrightReiterated RatingBuy$35.00High
4/21/2020Needham & Company LLCInitiated CoverageBuy$50.00High
3/12/2020Maxim GroupReiterated RatingBuy$40.00High
2/14/2020LADENBURG THALM/SH SHReiterated RatingBuyHigh
1/9/2020HC WainwrightReiterated RatingBuy$35.00Low
1/9/2020LADENBURG THALM/SH SHReiterated RatingBuy$60.00Medium
12/16/2019HC WainwrightReiterated RatingBuy$35.00Low
11/7/2019Needham & Company LLCReiterated RatingBuy$50.00Low
11/5/2019LADENBURG THALM/SH SHReiterated RatingBuy$60.00Low
10/18/2019Needham & Company LLCSet TargetBuy$50.00Low
8/19/2019Brookline Capital ManagementReiterated RatingBuyHigh
8/12/2019Needham & Company LLCReiterated RatingBuy$50.00Low
7/31/2019AegisInitiated CoverageBuyMedium
7/24/2019Maxim GroupSet TargetBuy$40.00Low
5/24/2019LADENBURG THALM/SH SHSet TargetBuy$60.00Low
5/12/2019Needham & Company LLCReiterated RatingBuy$50.00Medium
4/16/2019Needham & Company LLCReiterated RatingBuy$50.00Medium
3/18/2019Maxim GroupReiterated RatingBuy$40.00High
1/4/2019Brookline Capital ManagementReiterated RatingBuyHigh
11/13/2018Maxim GroupSet TargetBuy$40.00Low
10/23/2018HC WainwrightSet TargetBuy$50.00Low
10/16/2018Maxim GroupLower TargetBuy ➝ Buy$60.00 ➝ $40.00High
8/17/2018HC WainwrightSet TargetBuy$50.00Low
8/10/2018Needham & Company LLCSet TargetBuy$50.00Medium
8/10/2018Maxim GroupReiterated RatingBuy$60.00High
7/11/2018HC WainwrightSet TargetBuy$50.00High
7/11/2018Needham & Company LLCUpgradeHold ➝ Buy$50.00High
6/27/2018Maxim GroupInitiated CoverageBuy$60.00High
5/24/2018LADENBURG THALM/SH SHInitiated CoverageBuy$90.00Low
5/8/2018Roth CapitalInitiated CoverageBuy$60.00Low
5/7/2018HC WainwrightInitiated CoverageBuy$50.00High
(Data available from 1/27/2018 forward)

News Sentiment Rating

1.54 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/1/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2023

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

SCYNEXIS logo
SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Read More

Today's Range

Now: $1.75
Low: $1.72
High: $1.80

50 Day Range

MA: $1.89
Low: $1.44
High: $2.49

52 Week Range

Now: $1.75
Low: $1.42
High: $5.27

Volume

77,369 shs

Average Volume

85,066 shs

Market Capitalization

$57.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Frequently Asked Questions

What sell-side analysts currently cover shares of SCYNEXIS?

The following Wall Street sell-side analysts have issued research reports on SCYNEXIS in the last year: Brookline Capital Acquisition Corp., HC Wainwright, Maxim Group, and StockNews.com.
View the latest analyst ratings for SCYX.

What is the current price target for SCYNEXIS?

3 Wall Street analysts have set twelve-month price targets for SCYNEXIS in the last year. Their average twelve-month price target is $7.67, suggesting a possible upside of 338.1%. HC Wainwright has the highest price target set, predicting SCYX will reach $8.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $7.00 for SCYNEXIS in the next year.
View the latest price targets for SCYX.

What is the current consensus analyst rating for SCYNEXIS?

SCYNEXIS currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SCYX will outperform the market and that investors should add to their positions of SCYNEXIS.
View the latest ratings for SCYX.

What other companies compete with SCYNEXIS?

Other companies that are similar to SCYNEXIS include Bolt Biotherapeutics, Hepion Pharmaceuticals, Infinity Pharmaceuticals, Applied Therapeutics and Pyxis Oncology. Learn More about companies similar to SCYNEXIS.

How do I contact SCYNEXIS's investor relations team?

SCYNEXIS's physical mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company's listed phone number is (201) 884-5485 and its investor relations email address is [email protected] The official website for SCYNEXIS is www.scynexis.com. Learn More about contacing SCYNEXIS investor relations.